Hi Lisa,

More exciting news in the adjuvant melanoma world! The KEYNOTE-054 trial is a large (1019 patients) phase III trial which compared adjuvant pembrolizumab to placebo in patients with resected high risk melanoma (IIIA with > 1mm metastasis, IIIB and IIIC). Pembrolizumab 200 mg or placebo was given IV every three weeks for up to one year. Pembrolizumab reduced the risk of recurrence by 43% in the study population compared to placebo. There were no new safety concerns noted, meaning the usual immune related toxicities for pembro were seen. The study is ongoing and data on overall survival, distant metastases-free survival and outcome measures specifically for PD-L1 positive patients will also be reported. Full results are to be shared at an upcoming medical meeting. I look forward to hearing the additional results! It is wonderful to have so much to talk about in the melanoma world.